Announcement

Collapse
No announcement yet.

Stem Cells Transl Med . SARS-CoV-2 research using human pluripotent stem cells and organoids

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Stem Cells Transl Med . SARS-CoV-2 research using human pluripotent stem cells and organoids


    Stem Cells Transl Med


    . 2021 Jul 24.
    doi: 10.1002/sctm.21-0183. Online ahead of print.
    SARS-CoV-2 research using human pluripotent stem cells and organoids


    Sayaka Deguchi 1 , Ángel Serrano-Aroca 2 , Murtaza M Tambuwala 3 , Bruce D Uhal 4 , Adam M Brufsky 5 , Kazuo Takayama 1



    Affiliations

    Abstract

    Experimental cell models are indispensable for clarifying the pathophysiology of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and for developing therapeutic agents. To recapitulate the symptoms and drug response of COVID-19 patients in vitro, SARS-CoV-2 studies using physiologically relevant human embryonic stem (ES)/induced pluripotent stem (iPS) cell-derived somatic cells and organoids are ongoing. These cells and organoids have been used to show that SARS-CoV-2 can infect and damage various organs including the lung, heart, brain, intestinal tract, kidney, and pancreas. They are also being used to develop COVID-19 therapeutic agents, including evaluation of their antiviral efficacy and safety. The relationship between COVID-19 aggravation and human genetic backgrounds has been investigated using genetically modified ES/iPS cells and patient-derived iPS cells. This review summarizes the latest results and issues of SARS-CoV-2 research using human ES/iPS cell-derived somatic cells and organoids.

    Keywords: COVID-19; SARS-CoV-2; human ES cells; human iPS cells; organoids.

Working...
X